web analytics

Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light

FluoGuide A/S’s (“FluoGuide”, ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve the radicality of surgery in different types of cancer. Today data was presented at World Molecular Imaging Congress 2019 (WMIC) in Montreal, demonstrating how FG001 for in vivo fluorescent guidance improved surgical resection of metastatic pancreatic cancer in comparison with traditional white light surgery.
Pancreatic cancer remains one of the deadliest cancers, and the one and five-year survival rates have been reported as 15% and 3% (

Source: Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.